Db07107

Names

[ Name ]:
Db07107

Biological Activity

[Description]:

DB07107 is a potent drug resistant T315I mutant Bcr-Abl tyrosine kinase inhibitor. DB07107 is also a potent Akt1 inhibitor with an IC50 value of 360 nM[1][2].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Bcr-Abl

Signaling Pathways >> PI3K/Akt/mTOR >> Akt

[Target]

Bcr-AblT315I

Akt1:360 nM (IC50)

[In Vitro]

DB07107 is more effective in blocking drug-resistant T315I mutant than the wild-type Bcr-Abl. DB07107 (C23H22N4O) from DrugBank showed the highest binding energy with XP score of -14.045 kcal/mol[1].

[References]

[1]. Banavath HN, et al. Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study. Sci Rep. 2014 Nov 10;4:6948.

[2]. Li Q, et al. Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1679-85.

Chemical & Physical Properties

[ Molecular Formula ]:
C₂₃H₂₂N₄O

[ Molecular Weight ]:
370.45

Safety Information

[ Hazard Codes ]:
Xi

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.